This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T…

Non-Hodgkin LymphomaB-cell Non-Hodgkin Lymphoma (B-NHL)Mantle Cell Lymphoma (MCL)+1 more

~Estimated

~$10 – $6,250

University of Colorado, DenverNCT05098613

Phase 1

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-H…

B-cell Non-Hodgkin Lymphoma (B-NHL)

~Estimated

~$10 – $8,750

Cellectis S.A.NCT05607420